Your browser doesn't support javascript.
loading
Immunotherapy for Prostate Cancer: Where We Are Headed.
Schepisi, Giuseppe; Farolfi, Alberto; Conteduca, Vincenza; Martignano, Filippo; De Lisi, Delia; Ravaglia, Giorgia; Rossi, Lorena; Menna, Cecilia; Bellia, Salvatore Roberto; Barone, Domenico; Gunelli, Roberta; De Giorgi, Ugo.
Afiliação
  • Schepisi G; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. giuseppe.schepisi@irst.emr.it.
  • Farolfi A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. alberto.farolfi@irst.emr.it.
  • Conteduca V; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. vincenza.conteduca@irst.emr.it.
  • Martignano F; Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. filippo.martignano@gmail.com.
  • De Lisi D; Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. d.delisi@unicampus.it.
  • Ravaglia G; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. giorgia.ravaglia@irst.emr.it.
  • Rossi L; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. lorena.rossi@irst.emr.it.
  • Menna C; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. cecilia.menna@irst.emr.it.
  • Bellia SR; Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. salvatore.bellia@irst.emr.it.
  • Barone D; Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. domenico.barone@irst.emr.it.
  • Gunelli R; Urology Unit, Forlì Hospital, Romagna Local Health Service, 47100 Forlì, Italy. r.gunelli@ausl.fo.it.
  • De Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy. ugo.degiorgi@irst.emr.it.
Int J Mol Sci ; 18(12)2017 Dec 05.
Article em En | MEDLINE | ID: mdl-29206214
ABSTRACT
Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imunoterapia Limite: Animals / Humans / Male Idioma: En Revista: Int J Mol Sci Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Imunoterapia Limite: Animals / Humans / Male Idioma: En Revista: Int J Mol Sci Ano de publicação: 2017 Tipo de documento: Article